TSX:IMV Archives - Spark Newswire

3 minute read

IMV Initiates Restructuring Proceedings Under The CCAA To Complete The Review Of Its Strategic Alternatives

May 1, 12:32 PM

IMV Inc. (the "Company" or "IMV") (NASDAQ:IMV, TSX:IMV), a clinical-stage biopharmaceutical Company developing a portfolio of immune-educating therapies based on its novel DPX® platform to treat solid and

IMV

2 minute read

News

IMV Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency

By Happy Mohamed

March 31, 4:21 PM

IMV Inc. ("IMV" or the "Company") (NASDAQ:IMV, TSX:IMV), a clinical-stage company developing a portfolio of immune-educating therapies based on its novel DPX® platform to treat solid and

IMV

1 minute read

IMV Announced Update and Planned 2023 Milestones to Advance Clinical Development of its Lead Therapeutic, MVP-S; IMV Expects Its Current Cash Position Will Be Sufficient To Fund Operations Into The Second Half of 2023

By Charles Gross

January 8, 8:38 PM

IMV Inc. (Nasdaq: IMV; TSX: IMV) today outlined its planned 2023 milestones to advance the clinical development of its lead therapeutic, maveropepimut-S (MVP-S). Presenting details on initial response data from the ongoing VITALIZE DLBCL trial at the Immuno-Oncology 360° conference on February 10, 2023 Expects preliminary clinical response data from the AVALON Phase 2b trial in H2 2023

IMV

Feed Symbols: TSX:IMV

IMV Initiates Restructuring Proceedings Under The CCAA To Complete The Review Of Its Strategic Alternatives

IMV Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency

IMV Announced Update and Planned 2023 Milestones to Advance Clinical Development of its Lead Therapeutic, MVP-S; IMV Expects Its Current Cash Position Will Be Sufficient To Fund Operations Into The Second Half of 2023